Get the Stockscreener App
0.8489
0.05%
-0.0122
Precigen Inc stock is traded at $0.8489, with a volume of 121.02K.
It is down -0.05% in the last 24 hours and down -9.80% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$0.8367
Open:
$0.84
24h Volume:
121.02K
Relative Volume:
0.16
Market Cap:
$237.60M
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
5.6593
EPS:
0.15
Net Cash Flow:
$-68.47M
1W Performance:
-5.28%
1M Performance:
-9.80%
6M Performance:
-39.83%
1Y Performance:
-24.32%
1-Day Range:
$0.8317
$0.8499
1-Week Range:
$0.7739
$0.9257
52-Week Range:
$0.7739
$1.93
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| PGEN | 0.8462 | 237.60M | 6.23M | -95.90M | -68.47M | 0.15 |
| VRTX | 446.95 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.11 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.63 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.00 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.98 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Insiders Sold Precigen Prematurely At US$1.41 With Stock Trading Higher - Simply Wall St
Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86% - Yahoo Finance
Precigen (NASDAQ:PGEN) Given Buy Rating at HC Wainwright - Defense World
HC Wainwright Reduces Earnings Estimates for Precigen - MarketBeat
PGEN stock touches 52-week low at $0.78 amid market challenges - Investing.com Canada
HC Wainwright Reiterates Buy Rating for Precigen (NASDAQ:PGEN) - MarketBeat
Precigen Inc. (PGEN) Quarterly 10-Q Report - Quartzy
Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Precigen Inc (PGEN) Q3 2024 Earnings: EPS Misses at $(0.09), Rev - GuruFocus.com
Precigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Precigen earnings missed, revenue fell short of estimates By Investing.com - Investing.com UK
Precigen Reports Third Quarter 2024 Financial Results and Business Updates - Nasdaq
Precigen (NASDAQ:PGEN) Shares Cross Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Precigen CEO to Present at Stifel 2024 Healthcare Conference: Gene Therapy Innovation Spotlight | PGEN Stock News - StockTitan
Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Price Target from Brokerages - Defense World
Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Target Price from Analysts - MarketBeat
PGEN (Precigen) EBITDA per Share : $-0.52 (TTM As of Jun. 2024) - GuruFocus.com
Precigen Announces Pricing of $30.0 Million Public Offering of C - GuruFocus.com
Iridian Asset Management LLC CT Grows Stock Position in Precigen, Inc. (NASDAQ:PGEN) - MarketBeat
PGEN stock touches 52-week low at $0.82 amid market challenges - Investing.com Australia
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th - GuruFocus.com
High Growth Tech Stocks To Watch In October 2024 - Simply Wall St
Should you Hold Precigen (PGEN)? - Insider Monkey
Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
A company insider recently bought 58,823 shares of Precigen Inc [PGEN]. Should You Buy? - Knox Daily
Precigen reclaims rights after terminating license agreement By Investing.com - Investing.com Australia
Precigen Inc (PGEN) stock analysis: A simple moving average approach - US Post News
Precigen reclaims rights after terminating license agreement - Investing.com India
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Precigen Regains Full Control of Technology Post Agreement Termination - TipRanks
Precigen : Termination of Material Agreement Form 8 K - Marketscreener.com
Upward Trajectory: Precigen Inc (PGEN) Posts a Slidee, Closing at 0.85 - The Dwinnex
When Will Precigen, Inc. (NASDAQ:PGEN) Turn A Profit? - Simply Wall St
PGEN stock touches 52-week low at $0.83 amid market challenges - Investing.com
PGEN’s latest rating updates from top analysts. - Knox Daily
Is Precigen Inc (PGEN) positioned for future growth? - SETE News
SVP, IP Affairs Perez Jeffrey Thomas acquire 58,823 shares of Precigen Inc [PGEN] - Knox Daily
How to interpret Precigen Inc (PGEN)’s stock chart patterns - US Post News
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
Financial Analysis: Precigen Inc (PGEN)’s Ratios Unveil Key Insights - The Dwinnex
Precigen Inc (PGEN) receives an Underweight rating from JP Morgan - Knox Daily
Precigen's SWOT analysis: biotech firm's stock rides on PRGN-2012 success - Investing.com
Precigen Inc (PGEN)’s stock performance: a year in review - US Post News
Biotech Co. Precigen Announces IP Exec's Departure - Law360
Precigen Inc (PGEN) may enjoy gains as insiders got busy in the recent days - Knox Daily
Precigen senior VP Jeffrey Perez quits - Investing.com
J.P. Morgan cuts Precigen to underweight, cites burn rate - MSN
Precigen Inc Inc. (PGEN) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Precigen Inc [NASDAQ: PGEN] Sees Increase in Stock Value - Knox Daily
What is Precigen Inc (PGEN) Stock Return on Shareholders’ Capital? - SETE News
Investing in Precigen Inc (PGEN): What You Must Know - Knox Daily
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):